Lloyd Mitchell Segal - Jan 30, 2023 Form 4 Insider Report for Repare Therapeutics Inc. (RPTX)

Signature
/s/ Steve Forte, Attorney-in-Fact
Stock symbol
RPTX
Transactions as of
Jan 30, 2023
Transactions value $
$0
Form type
4
Date filed
2/1/2023, 08:44 PM
Previous filing
Jan 24, 2022
Next filing
Mar 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPTX Common Shares Award $0 +78.6K +1282.03% $0.00 84.7K Jan 30, 2023 Direct F1, F2
holding RPTX Common Shares 94.5K Jan 30, 2023 See footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RPTX Employee Stock Option (right to buy) Award $0 +344K $0.00 344K Jan 30, 2023 Common Shares 344K $12.42 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. Thirty-three and one third percent (33 1/3%) of the RSUs shall vest on each of January 30, 2024, January 30, 2025 and January 30, 2026, subject to Reporting Person continuing to provide service through each such date.
F2 Includes 398 shares and 729 shares acquired on August 13, 2021 and February 15, 2022, respectively, under the Issuer's employee stock purchase plan.
F3 These securities are registered in the name of Arvala Inc. (f/k/a 3996953 Canada Inc., the "Company"). The Reporting Person is the sole stockholder of the Company.
F4 Twenty-five percent (25%) of the shares subject to the option shall vest on January 30, 2024, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.